Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Long-term Cardiovascular Risk in Cured Cushing's Patients

This study has been withdrawn prior to enrollment.
(No patients were enrolled.)
Information provided by (Responsible Party):
Anne Klibanski, MD, Massachusetts General Hospital Identifier:
First received: April 13, 2009
Last updated: April 29, 2015
Last verified: April 2015
The purpose of this study is to determine whether subjects who have been affected by Cushing's disease in the past maintain some different characteristics compared with subjects who have never been diagnosed with the disease.

Cushing's Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Role of Adipokines in Long-term Cardiovascular Risk in Cured Cushing's Patients

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • adipokine measurements [ Time Frame: baseline ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
serum, urine

Enrollment: 0
Study Start Date: October 2008
Estimated Study Completion Date: October 2010
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
cured Cushing's disease


Ages Eligible for Study:   35 Years to 55 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Cured Cushing's disease

Inclusion Criteria:

  • patients who have been cured of Cushing's disease at least 5 years ago.

Exclusion Criteria:

  • patients who have been cured of Cushing's disease more than 15 years ago.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00881283

United States, Massachusetts
Neuroendocrine Clinical Center
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Anne Klibanski, MD Massachusetts General Hospital
  More Information

Responsible Party: Anne Klibanski, MD, PI, Massachusetts General Hospital Identifier: NCT00881283     History of Changes
Other Study ID Numbers: 2008-p-001379 
Study First Received: April 13, 2009
Last Updated: April 29, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Cushing's disease

Additional relevant MeSH terms:
Pituitary ACTH Hypersecretion
ACTH-Secreting Pituitary Adenoma
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pituitary Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site processed this record on October 26, 2016